Predictive modelling for high-risk stage II colon cancer using auto-artificial intelligence

被引:1
作者
Ishizaki, Tetsuo [1 ]
Mazaki, Junichi [1 ]
Enomoto, Masanobu [1 ]
Udo, Ryutaro [1 ]
Tago, Tomoya [1 ]
Kasahara, Kenta [1 ]
Nagakawa, Yuichi [1 ]
机构
[1] Tokyo Med Univ, Dept Gastrointestinal & Pediat Surg, Shinjuku Ku, 6-7-1 Nishi, Tokyo 1600023, Japan
关键词
Predictive modelling; Stage II colon cancer; High-risk; Auto-artificial intelligence; Prediction; Adjuvant chemotherapy; ADJUVANT CHEMOTHERAPY; CONTROLLED-TRIAL; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; GUIDELINES; THERAPY; SOCIETY;
D O I
10.1007/s10151-022-02685-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Recently, stratification of high-risk stage II colon cancer (CC) and the need for adjuvant chemotherapy have been the focus of attention. The aim of this retrospective study was to define high-risk factors for recurrent stage II CC using Prediction One auto-artificial intelligence (AI) software and develop a new predictive model for high-risk stage II CC. Methods The study included 259 consecutive pathological stage II CC patients undergoing curative resection at our institution between January 2000 and December 2016. Prediction One software with five-fold cross-validation was used to create a predictive model and receiver operating characteristic (ROC) curve. Predictive accuracy of AI was evaluated using the area under the ROC curve (AUC). We also evaluated the importance of variables (IOV) using a method based on permutation feature importance (IOV > 0.01 defined high-risk factors) to evaluate disease-free survival (DFS). Results The median observation period was 6.1 (range = 0.3-15.8) years. Thirty-seven patients had recurrence (14.3%); the AUC of the AI model was 0.775. Preoperative carcinoembryonic antigen > 5.0 ng/mL (IOV = 0.047), venous invasion (IOV = 0.014), and obstruction (IOV = 0.012) were high-risk factors contributing to cancer recurrence. Patients with 2-3 high-risk factors had lower 5-year DFS than those with 0-1 factor (87.4% vs 62.7%, p < 0.001). Conclusions We developed a new predictive model that could predict recurrent high-risk stage II CC with high probability using auto-AI Prediction One software. Patients with >= 2 of the aforementioned factors are considered to have high risks for recurrent stage II CC and may benefit from adjuvant chemotherapy.
引用
收藏
页码:183 / 188
页数:6
相关论文
共 19 条
  • [1] American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
    Benson, AB
    Schrag, D
    Somerfield, MR
    Cohen, AM
    Figueredo, AT
    Flynn, PJ
    Krzyzanowska, MK
    Maroun, J
    McAllister, P
    Van Cutsem, E
    Brouwers, M
    Charette, M
    Haller, DG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3408 - 3419
  • [2] Japanese Society for Cancer of the Colon and Rectum (JS']JSCCR) guidelines 2019 for the treatment of colorectal cancer
    Hashiguchi, Yojiro
    Muro, Kei
    Saito, Yutaka
    Ito, Yoshinori
    Ajioka, Yoichi
    Hamaguchi, Tetsuya
    Hasegawa, Kiyoshi
    Hotta, Kinichi
    Ishida, Hideyuki
    Ishiguro, Megumi
    Ishihara, Soichiro
    Kanemitsu, Yukihide
    Kinugasa, Yusuke
    Murofushi, Keiko
    Nakajima, Takako Eguchi
    Oka, Shiro
    Tanaka, Toshiaki
    Taniguchi, Hiroya
    Tsuji, Akihito
    Uehara, Keisuke
    Ueno, Hideki
    Yamanaka, Takeharu
    Yamazaki, Kentaro
    Yoshida, Masahiro
    Yoshino, Takayuki
    Itabashi, Michio
    Sakamaki, Kentaro
    Sano, Keiji
    Shimada, Yasuhiro
    Tanaka, Shinji
    Uetake, Hiroyuki
    Yamaguchi, Shigeki
    Yamaguchi, Naohiko
    Kobayashi, Hirotoshi
    Matsuda, Keiji
    Kotake, Kenjiro
    Sugihara, Kenichi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (01) : 1 - 42
  • [3] Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer
    Ishiguro, Megumi
    Mochizuki, Hidetaka
    Tomita, Naohiro
    Shimada, Yasuhiro
    Takahashi, Keiichi
    Kotake, Kenjiro
    Watanabe, Masahiko
    Kanemitsu, Yukihide
    Ueno, Hideki
    Ishikawa, Toshiaki
    Uetake, Hiroyuki
    Matsui, Shigeyuki
    Teramukai, Satoshi
    Sugihara, Kenichi
    [J]. BMC CANCER, 2012, 12
  • [4] Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Labianca, R.
    Nordlinger, B.
    Beretta, G. D.
    Mosconi, S.
    Mandala, M.
    Cervantes, A.
    Arnold, D.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 : 64 - 72
  • [5] LABIANCA R, 1995, LANCET, V345, P939
  • [6] A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial
    Matsuda, Chu
    Ishiguro, Megumi
    Teramukai, Satoshi
    Kajiwara, Yoshiki
    Fujii, Shoichi
    Kinugasa, Yusuke
    Nakamoto, Yoshihiko
    Kotake, Masanori
    Sakamoto, Yoshiyuki
    Kurachi, Kiyotaka
    Maeda, Atsuyuki
    Komori, Koji
    Tomita, Naohiro
    Shimada, Yasuhiro
    Takahashi, Keiichi
    Kotake, Kenjiro
    Watanabe, Masahiko
    Mochizuki, Hidetaka
    Nakagawa, Yoko
    Sugihara, Kenichi
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 96 : 54 - 63
  • [7] A Novel Predictive Model for Anastomotic Leakage in Colorectal Cancer Using Auto-artificial Intelligence
    Mazaki, Junichi
    Katsumata, Kenji
    Ohno, Yuki
    Udo, Ryutaro
    Tago, Tomoya
    Kasahara, Kenta
    Kuwabara, Hiroshi
    Enomoto, Masanobu
    Ishizaki, Tetsuo
    Nagakawa, Yuichi
    Tsuchida, Akihiko
    [J]. ANTICANCER RESEARCH, 2021, 41 (11) : 5821 - 5825
  • [8] A Novel Prediction Model for Colon Cancer Recurrence Using Auto-artificial Intelligence
    Mazaki, Junichi
    Katsumata, Kenji
    Ohno, Yuki
    Udo, Ryutaro
    Tago, Tomoya
    Kasahara, Kenta
    Kuwabara, Hiroshi
    Enomoto, Masanobu
    Ishizaki, Tetsuo
    Nagakawa, Yuichi
    Tsuchida, Akihiko
    [J]. ANTICANCER RESEARCH, 2021, 41 (09) : 4629 - 4636
  • [9] Colon cancer survival rates with the new American Joint Committee on cancer sixth edition staging
    O'Connell, JB
    Maggard, MA
    Ko, CY
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (19): : 1420 - 1425
  • [10] Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer
    OConnell, MJ
    Mailliard, JA
    Kahn, MJ
    MacDonald, JS
    Haller, DG
    Mayer, RJ
    Wieand, HS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) : 246 - 250